ReShape Lifesciences Inc. (RSLS) Misses Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ReShape Lifesciences Announces Record Revenue for First Quarter 2018
May 14, 2018 4:04 PM EDTSAN CLEMENTE, Calif., May 14, 2018 /PRNewswire/ -- ReShape Lifesciences Inc. (NASDAQ: RSLS), a developer of minimally invasive medical devices to treat obesity and metabolic diseases, today reported financial results for the three months ended March 31, 2018. Â
Recent Highlights and Accomplishments
Achieved record revenues of $950 thousand for the first quarter of 2018 Sold 521 ReShape BalloonsTM in the quarter, a 47% increase compared to the fourth quarter of 2017 Placed 61 ReShape vBlocTM units in the first quarter of 2018, as compared to 21 in the fourth quarter of 2017 Signed a... More